Table 2.

Pharmacogenetic studies of symptomatic remission conducted in Sequenced Treatment Alternatives to Relieve Depression (STAR^*D)

Study and gene	Marker	p	Sample N	Phenotype definitiona	Observations
Cabanero et al. (39)			1,914	NIMH
PDE1A	rs1549870	ns
PDE9A	rs729861	ns
PDE11A	rs4893975	ns
	rs6433687	ns
	rs3770016	ns
	rs1880916	ns
Hu et al. (36)			1,655	NIMH	Association with adverse effect burden
SLC6A4	5-HTTLPR	ns
Mrazek et al. (37)			1,503	Mayo Clinic	Adverse effect burden was not included in the phenotype. VNTR findings were significant only in the non-Hispanic white subsampleb
SLC6A4	5-HTTLPR	.04
	Intron 2	ns
	VNTR	.04
	rs25531	ns
Lekman et al. (38)			1,809	NIMH
FKBP5	rs1360780	ns
	rs4713916	.003
	rs3800373	ns
Paddock et al. (35)			1,816	NIMH
GRIK4	rs1954787	<.001
Peters et al. (63)			1,953	UCSF & NIMH
HTR2A	rs1923884	.01
Peters et al. (63) and McMahon et al. (32)			1,953 and 1,149	UCSF & NIMH
HTR2A	rs7997012	<.001
McMahon et al. (32)		<.001
HTR2A	rs1928040	.045	1,148	UCSF & NIMH
HTR2A	rs6313	ns	1,183	UCSF & NIMH
Domschke et al. (41)		ns	1,953	NIMH	rs6265 (val66met)
BDNF	rs1519479	ns
	rs2203877	ns
	rs1519480	ns
	rs6265	ns
	rs11030104	ns
	rs12273363	ns
	rs7931247	ns
	rs1491850	ns
	rs7119334	ns
	rs10742184	ns
Perlis et al. (31)			1,554	MGH	Remission achieved at STAR*D level 2
KCNK2	rs12031300	ns
	rs2841616	.003
	rs7538655	ns
	rs7549184	.03
	rs10494996	.01
	rs2841608	.003
	rs17546779	ns
	rs12136349	.003
	rs10779646	.03

^aNIMH, National Institute of Mental Health; UCSF, University of California, San Francisco; MGH, Massachusetts General Hospital

^bVNTR, variable-number tandem repeats